دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Going Beyond a Treat-To-Target to a Treat-To-Clear and a Treat-To-Trough Therapeutic Strategy in Patients with Inflammatory Bowel Disease?
Natália Sousa Freitas Queiroz, Adam S Cheifetz, Konstantinos Papamichael
doi : 10.1093/ecco-jcc/jjad014
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 825–826
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Hannah Gordon, Livia Biancone, Gionata Fiorino, Konstantinos H Katsanos, Uri Kopylov, Eman Al Sulais, Jordan E Axelrad, Karthiha Balendran, Johan Burisch, Lissy de Ridder, Lauranne Derikx, Pierre Ellul, Thomas Greuter, Marietta Iacucci, Caroline Di Jiang, Christina Kapizioni, Konstantinos Karmiris, Julien Kirchgesner, David Laharie, Triana Lobatón, Tamás Molnár, Nurulamin M Noor, Rohit Rao, Simone Saibeni, Michael Scharl, Stephan R Vavricka, Tim Raine
doi : 10.1093/ecco-jcc/jjac187
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 827–854
Transmural Remission Characterized by High Biologic Concentrations Demonstrates Better Prognosis in Crohn’s Disease
Kento Takenaka, Ami Kawamoto, Yoshio Kitazume, Toshimitsu Fujii, Yumi Udagawa, Hiromichi Shimizu, Shuji Hibiya, Masakazu Nagahori, Kazuo Ohtsuka, Mamoru Watanabe, Ryuichi Okamoto
doi : 10.1093/ecco-jcc/jjac185
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 855–862
The importance and pathophysiology of transmural healing in patients with Crohn’s disease [CD] remains to be verified. We aimed to examine the association between serum concentrations of biologics and transmural remission evaluated via magnetic resonance enterography [MRE].
Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial
Stefan Schreiber, Brian G Feagan, Laurent Peyrin-Biroulet, Séverine Vermeire, Margaux Faes, Kristina Harris, Alessandra Oortwijn, Patrick Daniele, Haridarshan Patel, Silvio Danese
doi : 10.1093/ecco-jcc/jjad018
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 863–875
Ulcerative colitis [UC] impacts patients’ health-related quality of life [HRQoL]. We assessed HRQoL and an exploratory patient-level composite endpoint (‘Comprehensive Disease Control’ [CDC]) in individuals receiving filgotinib [an oral JAK1 preferential inhibitor] in the SELECTION trial.
Comparison of Restorative Proctocolectomy with and Without Defunctioning Loop Ileostomy in Patients with Ulcerative Colitis: A Systematic Review and Meta-analysis
Mark Donnelly, Odhrán K Ryan, Éanna J Ryan, Gary A Bass, Michael E Kelly, Deirdre McNamara, Maria Whelan, Paul C Neary, James M O’Riordan, Dara O Kavanagh
doi : 10.1093/ecco-jcc/jjad021
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 876–895
Restorative proctocolectomy [RPC] without a defunctioning loop ileostomy [DLI] in patients with ulcerative colitis [UC] remains controversial.
A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases
Wannee Kantasiripitak, Sebastian G Wicha, Debby Thomas, Ilse Hoffman, Marc Ferrante, Séverine Vermeire, Karen van Hoeve, Erwin Dreesen
doi : 10.1093/ecco-jcc/jjad009
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 896–908
Adequate infliximab concentrations during induction treatment are predictive for deep remission [corticosteroid-free clinical and endoscopic remission] at 6 months in children with inflammatory bowel diseases [IBD]. Under standard infliximab induction dosing, children often have low infliximab trough concentrations.
A Compendium of Mucosal Molecular Characteristics Provides Novel Perspectives on the Treatment of Ulcerative Colitis
Min-Jing Chang, Jia-Wei Hao, Jun Qiao, Miao-Ran Chen, Qian Wang, Qi Wang, Sheng-Xiao Zhang, Qi Yu, Pei-Feng He
doi : 10.1093/ecco-jcc/jjad011
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 909–918,
Ulcerative colitis [UC] is a complex heterogeneous disease. This study aims to reveal the underlying molecular features of UC using genome-scale transcriptomes of patients with UC, and to develop and validate a novel stratification scheme.
Serum N-Glycomic Biomarkers Predict Treatment Escalation in Inflammatory Bowel Disease
Archana Shubhakar, Bas C Jansen, Alex T Adams, Karli R Reiding, Nicholas T Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A Urbanowicz, Richard A Gardner, IBD-BIOM Consortium , Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L Fernandes, Daniel I R Spencer
doi : 10.1093/ecco-jcc/jjad012
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 919–932
Biomarkers to guide clinical decision making at diagnosis of inflammatory bowel disease [IBD] are urgently needed. We investigated a composite serum N-glycomic biomarker to predict future disease course in a discovery cohort of 244 newly diagnosed IBD patients.
Thioguanine is Effective as Maintenance Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Registry Study
Melek Simsek, Femke Schepers, Sigal Kaplan, Dirk van Asseldonk, Petra van Boeckel, Paul Boekema, Gerard Dijkstra, Herma Fidder, Ingrid Gisbertz, Frank Hoentjen, Bindia Jharap, Frank Kubben, Marleen de Leest, Maarten Meijssen, Ana Petrak, Else van de Poel, Maurice Russel, Adriaan A van Bodegraven, Chris J J Mulder, Nanne de Boer
doi : 10.1093/ecco-jcc/jjad013
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 933–942
Thioguanine is a well-tolerated and effective therapy for inflammatory bowel disease [IBD] patients. Prospective effectiveness data are needed to substantiate the role of thioguanine as a maintenance therapy for IBD.
Prospective Validation of the Lémann Index in Children: A Report From the Multicentre Image Kids Study
Gili Focht, Ruth Cytter Kuint, Mary-Louise C Greer, Li-Tal Pratt, Denise A Castro, Peter C Church, VÃctor Manuel Navas-López, Robert N Baldassano, Joachim Høg Mortensen, Florian Rieder, Baruch Yerushalmi, Anat Ilivitzki, Osnat Konen, Anne M Griffiths, Dan Turner
doi : 10.1093/ecco-jcc/jjad017
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 943–949
The Lémann Index [LI] and the recently updated LI are tools for measuring structural bowel damage in adults with Crohn’s disease [CD] but have not been evaluated in children. We aimed to validate the updated LI in the prospective multicentre ImageKids study of paediatric CD.
Perioperative Low-Dose Prednisolone Treatment Has Beneficial Effects on Postoperative Recovery and Anastomotic Healing in a Murine Colitis Model
Marie-Christin Weber, Jannick Bauer, Annalisa Buck, Zoé Clees, Reinhard Oertel, Atsuko Kasajima, Stefan Reischl, Dirk Wilhelm, Helmut Friess, Philipp-Alexander Neumann
doi : 10.1093/ecco-jcc/jjad002
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 950–959
High-dose glucocorticoid treatment has been identified as a risk factor for anastomotic leakage in patients with inflammatory bowel disease [IBD] undergoing bowel resection surgery. By contrast, active disease during surgery is also associated with elevated morbidity.
GATA6-AS1 Regulates Intestinal Epithelial Mitochondrial Functions, and its Reduced Expression is Linked to Intestinal Inflammation and Less Favourable Disease Course in Ulcerative Colitis
Katya E Sosnovski, Tzipi Braun, Amnon Amir, Danielle Moshel, Marina BenShoshan, Kelli L VanDussen, Nina Levhar, Haya Abbas-Egbariya, Katia Beider, Rakefet Ben-Yishay, Syed Asad Ali, Sean R Moore, Subra Kugathasan, Ifat Abramovich, Efrat Glick Saar, Batya Weiss, Iris Barshack, Eyal Gottlieb, Tamar Geiger, Shomron Ben-Horin, Igor Ulitsky, Jeffrey S Hyams, Lee A Denson, Yael Haberman
doi : 10.1093/ecco-jcc/jjad006
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 960–971
Widespread dysregulation of long non-coding RNAs [lncRNAs] including a reduction in GATA6-AS1 was noted in inflammatory bowel disease [IBD]. We previously reported a prominent inhibition of epithelial mitochondrial functions in ulcerative colitis [UC]. However, the connection between reduction of GATA6-AS1 expression and attenuated epithelial mitochondrial functions was not defined.
Rescue Therapies for Steroid-refractory Acute Severe Ulcerative Colitis: A Review
Javier P Gisbert, MarÃa José GarcÃa, MarÃa Chaparro
doi : 10.1093/ecco-jcc/jjad004
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 972–994
One-third of patients with acute severe ulcerative colitis [ASUC] are steroid-refractory. We aimed to review the different options for the management of steroid-refractory ASUC, including not only the standard treatment [cyclosporine and infliximab], but also most recently developed agents [such as vedolizumab, ustekinumab, and tofacitinib].
Vaccines in Children Exposed to Biological Agents In Utero and/or During Breastfeeding: Are They Effective and Safe?
Javier P Gisbert, MarÃa Chaparro
doi : 10.1093/ecco-jcc/jjad005
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 995–1009
Biological agents cross the placenta, resulting in detectable blood levels in the neonate. Neonatal vaccinations are essential to prevent serious infections.
Pathogenesis of Perianal Fistulising Crohn’s Disease: Current Knowledge, Gaps in Understanding, and Future Research Directions
Siyan Cao, Marco Colonna, Parakkal Deepak
doi : 10.1093/ecco-jcc/jjad008
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 1010–1022
Fistulising perianal involvement is a common presentation of Crohn’s disease. Perianal Crohn’s disease dramatically impairs patients’ social and sexual life and its management remains a critical challenge in field of inflammatory bowel disease.
Genetic Evidence for Causal Relationship Between Body Mass Index and Inflammatory Bowel Disease: A Mendelian Randomisation Study
Zhen Sun, Mengsi Liu
doi : 10.1093/ecco-jcc/jjad007
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Pages 1023–1024
Corrigendum to: The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study
doi : 10.1093/ecco-jcc/jjad016
Journal of Crohn's and Colitis, Volume 17, Issue 6, June 2023, Page 1025
